The application of the target and mechanism of action of regorafenib in tumor treatment

Regofenib is an oral multi-target tyrosine kinase inhibitor that can act on a variety of receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptors (VEGFR1-3), platelet derivatives Long factor receptor (PDGFR), KIT, RET and RAF etc. These targets play key roles in tumor angiogenesis, cell proliferation and metastasis, so regorafenib interferes with tumor growth and spread through a multi-target mechanism of action.

Regofenib can block tumor angiogenesis and reduce tumor blood supply by inhibiting the VEGFR and PDGFR signaling pathways, thereby inhibiting tumor growth. At the same time, it directly inhibits tumor cell proliferation and promotes apoptosis by inhibiting kinases such as KIT, RET, and RAF. In addition, the multi-target effect enables regorafenib to simultaneously intervene in multiple signals in the tumor microenvironment, enhance anti-tumor efficacy, and reduce the possibility of drug resistance.

Regofenib is mainly used clinically for the treatment of advanced colorectal cancer, gastrointestinal stromal tumors (GIST) and hepatocellular carcinoma (HCC). For patients who fail chemotherapy or whose previous targeted drugs are ineffective, regorafenib can significantly prolong progression-free survival and overall survival. At the same time, its multi-target characteristics enable it to show certain efficacy in some solid tumors and advanced multi-drug resistance cases, making it an important choice for the treatment of advanced tumors.

The advantage of regorafenib lies in its broad-spectrum multi-target action, convenient oral administration, and its ability to simultaneously act on angiogenesis and tumor cell proliferation. However, multi-target effects may also cause some side effects, such as hypertension, rash on hands and feet, fatigue, and abnormal liver function. Therefore, in clinical use, blood pressure, liver function and skin reactions need to be monitored regularly, and the dosage adjusted according to patient tolerance to ensure efficacy while reducing risks.

Reference link:https://www.drugs.com